Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements by 35+ Global Leaders, DelveInsight | Featuring Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma

Rhinitis treatment market is driven by several factors, including increasing prevalence, advancements in treatment options, growing awareness, and the ongoing development of new medications. According to DelveInsight, the Rhinitis pipeline comprises 35+ pharmaceutical and biotech companies actively developing 35+ therapeutic candidates targeting Rhinitis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Rhinitis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Rhinitis Therapeutics Market and the breakthroughs shaping its future trajectory.
Explore the Cutting-Edge Landscape of Rhinitis Drug Development @ https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Rhinitis Pipeline Report

DelveInsight's Rhinitis pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Rhinitis treatment.
In March 2025, the FDA approved Astepro (Azelastine Hydrochloride) nasal spray for over-the-counter use, making it the first nasal antihistamine available without a prescription for seasonal and perennial allergic rhinitis in adults and children aged 6 and older.
FDA approved Neffy, an epinephrine nasal spray, in August 2024. This provides a needle-free option for emergency treatment of severe allergic reactions, such as anaphylaxis. On another note, the FDA is reviewing the effectiveness of oral phenylephrine, a common decongestant, and may consider removing it from the market due to concerns over its ineffectiveness, encouraging the use of alternatives like nasal sprays and steroids such as Flonase.
In March 2024, XHANCE (Fluticasone Propionate) nasal spray was approved for treating chronic rhinosinusitis without nasal polyps in adults aged 18 and older. XHANCE is the first FDA-approved medication specifically for this condition, delivering a corticosteroid directly to the nasal passages.
Key Rhinitis companies such as Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Sanofi, Hanmi Pharmaceutical Company Limited, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha PHARM.CO.,LTD., Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Biomay AG, and others are evaluating new drugs for Rhinitis to improve the treatment landscape.
Promising Rhinitis pipeline therapies in various stages of development include REGN1908-1909, IRL201104, and others.

Rhinitis Overview:

Rhinitis is a condition marked by symptoms such as nasal congestion, runny nose or post-nasal drip, sneezing, and itching. It can stem from various causes and is generally categorized as either allergic or non-allergic. Allergic rhinitis, also known as hay fever, results from the immune system's overreaction to harmless substances like pollen, mold, dust mites, pet dander, or other environmental triggers. This response involves the release of histamine, leading to inflammation and classic allergy symptoms. Non-allergic rhinitis, on the other hand, is not caused by allergens and may be triggered by irritants like smoke, weather changes, or infections. Rhinitis often occurs alongside or before sinusitis, which is characterized by facial pressure, reduced sense of smell, and discolored nasal discharge. Diagnosis and management by an ENT specialist are recommended, with treatments varying based on the cause. These may include trigger avoidance, medications, or allergen immunotherapy such as allergy shots or sublingual tablets.

Download the Rhinitis sample report to know in detail about the Rhinitis treatment market @ https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Rhinitis Pipeline Analysis
The Rhinitis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Rhinitis Market.

Categorizes Rhinitis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Rhinitis drugs under development based on:

Stage of development

Rhinitis Route of administration

Target receptor

Monotherapy vs. combination therapy

Rhinitis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Rhinitis Licensing agreements

Funding and investment activities supporting future Rhinitis market advancement.

Unlock key insights into emerging Rhinitis therapies and market strategies here: https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Rhinitis Emerging Drugs

REGN1908-1909: Regeneron

REGN1908-1909 is a Phase III antibody therapy by Regeneron targeting the Fel d 1 cat allergen to block allergic responses. Developed using VelocImmune® technology, it aims to treat allergic rhinitis caused by cat allergies.

IRL201104: Revolo Biotherapeutics

IRL201104, derived from a natural immune-regulatory protein, aims to reset the immune system and offer long-term allergy relief. It rapidly reduces lung neutrophil infiltration after bronchial challenge, though its effect is short-lived. Currently, it's in Phase II trials for treating seasonal allergic rhinitis.

Rhinitis Pipeline Therapeutic Assessment

Rhinitis Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Rhinitis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Rhinitis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Rhinitis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Rhinitis therapies and key Rhinitis companies: https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Rhinitis Current Treatment Patterns
4. Rhinitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Rhinitis Late-Stage Products (Phase-III)
7. Rhinitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Rhinitis Discontinued Products
13. Rhinitis Product Profiles
14. Rhinitis Key Companies
15. Rhinitis Key Products
16. Dormant and Discontinued Products
17. Rhinitis Unmet Needs
18. Rhinitis Future Perspectives
19. Rhinitis Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Rhinitis pipeline reports offerings: https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.